Suppr超能文献

基于 nutlin 的选择性小分子 MDM2 降解剂的开发。

Development of selective small molecule MDM2 degraders based on nutlin.

机构信息

School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.

School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA; Gannan Medical University, Ganzhou, Jiangxi Province, 341000, PR China.

出版信息

Eur J Med Chem. 2019 Aug 15;176:476-491. doi: 10.1016/j.ejmech.2019.05.046. Epub 2019 May 17.

Abstract

Tumor suppressor protein p53 is important to the regulation of many cellular processes and the prevention of cancer development. In some cancer cells, the function of p53 is inhibited by murine double minute 2 protein (MDM2). To restore the function of p53, the inhibition or depletion of MDM2 has become a potential therapeutic treatment. We have successfully developed a series of small molecule MDM2 degraders that can promote the proteolysis of MDM2 oncoprotein, thus reactivating tumor suppressor p53. The superior degrader features a nutlin-based MDM2 ligand and a lenalidomide-based cereblon E3 ubiquitin ligase ligand with a short linker between the two ligands. At low nanomolar concentrations in RS4; 11 leukemia cells, this degrader promotes efficient degradation of MDM2. It also inhibits the proliferation of leukemia cells with an IC value of 3.2 nM and induces apoptosis effectively. All of these data indicate that MDM2 degraders are promising therapeutics for the treatment of cancers, such as leukemia.

摘要

抑癌蛋白 p53 对于调节多种细胞过程和预防癌症发生非常重要。在一些癌细胞中,p53 的功能被鼠双微体 2 蛋白(MDM2)抑制。为了恢复 p53 的功能,抑制或耗尽 MDM2 已成为一种潜在的治疗方法。我们已经成功开发了一系列小分子 MDM2 降解剂,可促进 MDM2 癌蛋白的蛋白水解,从而重新激活肿瘤抑制因子 p53。该高效降解剂的特点是基于 nutlin 的 MDM2 配体和基于 lenalidomide 的 cereblon E3 泛素连接酶配体,两者之间有一个短连接子。在 RS4;11 白血病细胞中,该降解剂在低纳摩尔浓度下可有效促进 MDM2 的降解。它还能以 3.2nM 的 IC 值抑制白血病细胞的增殖,并有效诱导细胞凋亡。所有这些数据表明,MDM2 降解剂是治疗白血病等癌症的有前途的治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验